An observational study in Diabetes Mellitus, Type 2 and Cardiovascular Diseases, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Johnson & Johnson.
Among the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson, this one is one of 2 that started in 2018, is one of 8 observational ones, and was the 61st registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 714,582 is above the median of 300 across 1,748 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 115 across the 54 interventional studies, 13,252 across the 8 observational. Of the 62 that completed or were terminated, 21 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The date of first exposure to the particular drug(s) in the database, where the exposure start is between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed and reported in this study.
Participants diagnosed with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease over a 4-year period 1 April 2013 and 15 May 2017 will be observed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For cohort with 'established cardiovascular disease - At least 1 occurrence of 'conditions indicating established cardiovascular disease' on or any time in the prior continuous observation time (which is at least 365 days long) prior to the index date
Exclusion Criteria:
- Participants with type 1 diabetes or secondary diabetes prior to or on the index date of exposure were excluded from the study
A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).
Drug: Canagliflozin
A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Canagliflozin
A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Empagliflozin
A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Empagliflozin
A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Dapagliflozin
A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Dapagliflozin
A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Empagliflozin · Drug: Dapagliflozin
A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Empagliflozin · Drug: Dapagliflozin
A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · Drug: Glucagon-like Peptide-1 (GLP-1) Agonist · Drug: Anti-hyperglycemic Agents (AHA)
A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · Drug: Glucagon-like Peptide-1 (GLP-1) Agonist · Drug: Anti-hyperglycemic Agents (AHA)
A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · Drug: Glucagon-like Peptide-1 (GLP-1) Agonist · Drug: Anti-hyperglycemic Agents (AHA) · Drug: Thiazolidinediones (TZD) · Drug: Sulfonylureas (SU) · Drug: Insulin
A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors · Drug: Glucagon-like Peptide-1 (GLP-1) Agonist · Drug: Anti-hyperglycemic Agents (AHA) · Drug: Thiazolidinediones (TZD) · Drug: Sulfonylureas (SU) · Drug: Insulin
No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.
No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.
No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.
No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.
No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
Number of Hospitalizations for Heart Failure
Number of hospital admissions with a primary diagnosis of 'heart failure' will be reported.
Time frame: Approximately 4-years
Number of Participants with Below Knee Lower Extremity Amputation Events
Number of participants with new below-knee lower extremity amputation procedures, excluding recent (within 30 day) revisions will be reported.
Time frame: Approximately 4-years
Ran from Feb 2018 to primary completion in Apr 2018, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC →